Xponance Inc. Boosts Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Xponance Inc. boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,240 shares of the company’s stock after acquiring an additional 315 shares during the period. Xponance Inc.’s holdings in Henry Schein were worth $1,331,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HSIC. Versant Capital Management Inc lifted its position in Henry Schein by 274.6% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $32,000 after acquiring an additional 335 shares during the last quarter. Venturi Wealth Management LLC lifted its position in Henry Schein by 3,347.1% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock valued at $41,000 after acquiring an additional 569 shares during the last quarter. Quent Capital LLC lifted its position in Henry Schein by 91.2% during the fourth quarter. Quent Capital LLC now owns 677 shares of the company’s stock valued at $47,000 after acquiring an additional 323 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Henry Schein by 23.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after acquiring an additional 143 shares during the last quarter. Finally, City State Bank purchased a new stake in Henry Schein during the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Down 1.5 %

NASDAQ:HSIC opened at $69.39 on Friday. The firm has a market capitalization of $8.62 billion, a P/E ratio of 28.56, a PEG ratio of 2.13 and a beta of 0.90. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.49. The company’s fifty day moving average price is $74.82 and its 200-day moving average price is $72.61. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.66 EPS. As a group, equities research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Barrington Research reissued an “outperform” rating and set a $90.00 target price on shares of Henry Schein in a research report on Wednesday, February 26th. Jefferies Financial Group upped their price target on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Mizuho initiated coverage on shares of Henry Schein in a research note on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price target on the stock. Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and upped their price target for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Finally, UBS Group cut their price target on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 26th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $81.10.

Insider Activity at Henry Schein

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the transaction, the director now directly owns 24,805 shares of the company’s stock, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the transaction, the chief executive officer now directly owns 62,688 shares in the company, valued at approximately $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.